Staphylococcus Aureus Clinical Trial
Official title:
Acquisition and Persistence of Rifampicin Resistance in Staphylococcus Aureus During and After Treatment for Latent Tuberculosis
Two commonly used treatments for latent tuberculosis infection are either 4 months rifampicin or 6-9 months isoniazid. The invistigators will study the risk of acquisition of rifampicin resistance in commensal Staphylococcus aureus in persons treated with rifampicin versus in persons treated with isoniazide. Through repeated swab cultures before, during, and after treatment the investigators will also investigate potential accumulation of mutations associated with rifampicin resistance over time. Finally, household contacts to persons with rifampicin-resistant S. aureus will be examined to investigate whether onward transmission of rifampicin-resistant S. aureus occurs within households.
The use of rifampicin for treatment of latent tuberculosis has gained popularity due to a shorter treatment course compared with isoniazide (4 versus 6-9 months) since this can lead to a higher proportion of treatment completion. An estimated 25% of the global population is latently infected with tuberculosis. Hence, a shift towards rifampicin instead of isoniazide, which has a more narrow antibacterial spectrum, could have a large impact on the prevalence of rifampicin resistance among commensal bacteria with pathogenic potential, such as Staphylococcus aureus (S.aureus). The investigators will investigate the risk of acquisition of rifampicin resistance in commensal S.aureus during out-patient treatment for latent tuberculosis using 4 months rifampicin versus 6-9 months isoniazide at Skåne University Hospital in Malmö, Sweden. Swabs will be obtained from the nose, throat, groin and possible wounds for culture and resistance testing before, during and after cessation of treatment for latent tuberculosis. Whole genome sequencing will be used to analyze accumulation of mutations over time and to determine if it is the primarily detected S.aureus that develop resistance or if the individual is colonized by new, rifampicin-resistant S.aureus over the course of treatment. Household contacts to persons with rifampicin-resistant S.aureus will be examined to investigate onward spread of bacteria within a household. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01212120 -
The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections
|
N/A | |
| Completed |
NCT00801879 -
Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection
|
Phase 4 | |
| Terminated |
NCT03638947 -
Reducing Perioperative S. Aureus Transmission
|
N/A | |
| Recruiting |
NCT05331885 -
A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
|
Phase 3 | |
| Recruiting |
NCT05094570 -
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
|
Phase 4 | |
| Not yet recruiting |
NCT05092464 -
Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis
|
N/A | |
| Recruiting |
NCT05695196 -
Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant
|
Phase 1 | |
| Enrolling by invitation |
NCT04666532 -
S. Aureus Translocation From Skin and Nose to Periprosthetic Tissues
|
||
| Active, not recruiting |
NCT02572791 -
Staph Household Intervention for Eradication (SHINE)
|
Phase 4 | |
| Recruiting |
NCT04274348 -
Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum
|
N/A | |
| Enrolling by invitation |
NCT05880069 -
Clinical Outcomes in Patients With Infection by Resistant Microorganism
|
||
| Completed |
NCT01011335 -
Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
|
Phase 1/Phase 2 | |
| Completed |
NCT03816956 -
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
|
Phase 3 | |
| Not yet recruiting |
NCT04884958 -
A Study to Investigate the Transmission and Burden of PVL-MRSA in Households in Sri Lanka
|
||
| Completed |
NCT01105767 -
Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees
|
N/A | |
| Completed |
NCT00475930 -
Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates
|
N/A | |
| Completed |
NCT00507247 -
Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus
|
Phase 2 | |
| Recruiting |
NCT03220386 -
Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus (MSSA/MRSA) - Point-of-care-testing (POCT) in Clinical Decision Making
|
N/A | |
| Completed |
NCT03140423 -
Mupirocin-Iodophor ICU Decolonization Swap Out Trial
|
Phase 4 | |
| Not yet recruiting |
NCT03869593 -
Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria
|